Granahan Investment Management LLC lessened its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 24.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 191,397 shares of the company’s stock after selling 62,502 shares during the period. Granahan Investment Management LLC’s holdings in Stoke Therapeutics were worth $6,075,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently bought and sold shares of the business. Strs Ohio grew its holdings in Stoke Therapeutics by 9.4% during the 4th quarter. Strs Ohio now owns 7,000 shares of the company’s stock worth $222,000 after acquiring an additional 600 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Stoke Therapeutics by 31.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after acquiring an additional 658 shares during the period. Generali Investments Management Co LLC grew its holdings in Stoke Therapeutics by 41.0% during the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock worth $78,000 after acquiring an additional 718 shares during the period. Kestra Advisory Services LLC acquired a new stake in Stoke Therapeutics during the 4th quarter worth $26,000. Finally, Harbour Investments Inc. grew its holdings in Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after acquiring an additional 898 shares during the period.
Wall Street Analyst Weigh In
A number of analysts have commented on the stock. Canaccord Genuity Group lifted their target price on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Wall Street Zen lowered shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Needham & Company LLC boosted their price target on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Weiss Ratings lowered shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, Wolfe Research started coverage on shares of Stoke Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.83.
Stoke Therapeutics Trading Down 2.8%
Shares of NASDAQ STOK opened at $29.15 on Wednesday. The firm has a market cap of $1.82 billion, a PE ratio of -10.37 and a beta of 1.17. Stoke Therapeutics, Inc. has a 1-year low of $11.17 and a 1-year high of $40.22. The company has a fifty day moving average price of $32.12 and a 200 day moving average price of $32.36.
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. The firm had revenue of $6.23 million during the quarter, compared to analyst estimates of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. Equities research analysts forecast that Stoke Therapeutics, Inc. will post -3.22 EPS for the current year.
Insiders Place Their Bets
In related news, insider Barry Ticho sold 1,795 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $30.58, for a total value of $54,891.10. Following the completion of the transaction, the insider directly owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. This represents a 4.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company’s stock.
About Stoke Therapeutics
Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.
The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.
Featured Articles
- Five stocks we like better than Stoke Therapeutics
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report).
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
